Brokerages Set Crispr Therapeutics AG (CRSP) Price Target at $50.19

Shares of Crispr Therapeutics AG (NASDAQ:CRSP) have been assigned an average rating of “Hold” from the sixteen analysts that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $49.21.

Several equities research analysts have commented on CRSP shares. BTIG Research began coverage on Crispr Therapeutics in a research note on Thursday, February 7th. They set a “buy” rating and a $43.00 price target for the company. Zacks Investment Research raised Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research report on Thursday, January 3rd. SunTrust Banks reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, December 31st. Needham & Company LLC began coverage on Crispr Therapeutics in a research report on Sunday, December 9th. They issued a “buy” rating and a $38.72 target price for the company. Finally, BidaskClub raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, January 10th.

Shares of NASDAQ:CRSP opened at $38.70 on Tuesday. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -11.25 and a beta of 3.14. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $73.90.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, February 25th. The company reported ($0.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by ($0.14). The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $1.56 million. Crispr Therapeutics had a negative return on equity of 40.41% and a negative net margin of 331.84%. The business’s revenue was down 99.7% compared to the same quarter last year. Sell-side analysts anticipate that Crispr Therapeutics will post -3.46 EPS for the current fiscal year.

In other news, President Rodger Novak sold 8,693 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $40.01, for a total value of $347,806.93. Following the completion of the sale, the president now owns 1,024,534 shares of the company’s stock, valued at $40,991,605.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kurt Von Emster sold 72,934 shares of the stock in a transaction dated Tuesday, December 18th. The shares were sold at an average price of $29.85, for a total value of $2,177,079.90. The disclosure for this sale can be found here. In the last ninety days, insiders bought 153,682 shares of company stock valued at $3,700,718 and sold 198,937 shares valued at $7,166,383. 37.70% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of CRSP. Bank of America Corp DE boosted its holdings in Crispr Therapeutics by 26.5% in the second quarter. Bank of America Corp DE now owns 9,407 shares of the company’s stock valued at $553,000 after purchasing an additional 1,972 shares during the last quarter. California Public Employees Retirement System purchased a new position in Crispr Therapeutics in the second quarter valued at about $1,046,000. Northern Trust Corp boosted its holdings in Crispr Therapeutics by 51.9% in the second quarter. Northern Trust Corp now owns 24,121 shares of the company’s stock valued at $1,417,000 after purchasing an additional 8,241 shares during the last quarter. First Trust Advisors LP boosted its holdings in Crispr Therapeutics by 9.8% in the third quarter. First Trust Advisors LP now owns 93,347 shares of the company’s stock valued at $4,140,000 after purchasing an additional 8,295 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in Crispr Therapeutics in the third quarter valued at about $275,000. 43.07% of the stock is owned by hedge funds and other institutional investors.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

See Also: What is Compound Interest?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.